<DOC>
	<DOCNO>NCT02906722</DOCNO>
	<brief_summary>Few antimicrobial available treat ventilate associate pneumonia ( VAP ) cause Gram negative multi-resistant ( MDR ) bacteria . Colimycin often remain active antibiotic . The aim study demonstrate superiority nebulized colimycin intravenous colimycin treat VAP cause Gramnegative MDR bacteria .</brief_summary>
	<brief_title>Nebulized Intravenous Colistin Ventilator Associated-pneumonia</brief_title>
	<detailed_description>VAP frequent nosocomial infection critically ill patient affect length stay cost Intensive Care Unit . The increased incidence nosocomial infection cause MDR bacteria become major health problem worldwide . Nowadays , antimicrobial available treat Gram negative MDR VAP . Colimycin often remain active antibiotic . Treating VAP intravenous ( IV ) colimycin two main limitation : risk renal toxicity low tissue penetration . Nebulization colimycin offer possibility generate high lung tissue concentration , rapid bactericidal effect low systemic accumulation experimental model . To date however , study compare clinical effectiveness nebulized intravenous colimycin . We make hypothesis nebulized colimycin increase clinical cure rate VAP cause Gram negative MDR bacteria compare IV colimycin . Primary Objective : To demonstrate superiority nebulized colimycin intravenous colimycin treat VAP cause Gram-negative MDR bacteria . Secondary Objectives : 1 . To compare microbiological cure rate end treatment 2 . To compare VAP recurrence rate end treatment 3 . To compare lung superinfection rate end treatment 4 . To compare 28 day- 90 day-mortality 5 . To compare duration mechanical ventilation 6 . To compare length ICU stay 7 . To compare renal function colimycin administration 8 . To compare side effect result colimycin nebulization intravenous administration Ancillary study : In center , blood sample perform measure colistin peak trough plasma concentration Study design : This randomize , multicenter , double-blind phase III study 1 . Randomization : Patients randomly assign experimental group control group : Control group : patient receive simultaneously intravenous colimycin nebulized placebo . Experimental group : patient receive simultaneously nebulized colimycin intravenous infusion placebo . Dosing adjustment accord renal function intravenous infusion colimycin placebo . 2 . Aerosol generation : Nebulization perform vibrate plate nebulizer ( Aeroneb® Solo ) follow ventilator setting : - Constant flow volume-controlled mode - Inspiratory/expiratory ratio 1 - Tidal volume 6-8 ml/kg - Respiratory frequency 12-18/min - End-inspiratory pause 20 % To standardize nebulization procedure , checklist form complete nurse charge patient . 3 . Duration treatment : - 10 day group - In intubated patient , wean test authorize 4 day treatment . If patient extubated , aerosol discontinue whereas intravenous infusion continue ( placebo antibiotic ) day 10 - In tracheostomized patient : 10-day treatment nebulized intravenous therapy 4 . Combined intravenous administration antimicrobial authorize 5 . Serum microbiological sample - Serum creatinine measure daily baseline day 11 - Lower respiratory tract specimen day 5 day 11 intubate patient 6 . Survival follow-up day 28 90 day Study population : Adult mechanical ventilate patient VAP cause Gram-negative MDR bacteria . Sample size Power consideration : Data analyze triangular test . Assuming clinical cure rate day 11 65 % group treat nebulized colimycin 45 % group treat intravenous colimycin , mean sample size 134 patient require provide 80 % power , two-sided type I error rate 5 % . The 90th percentile number patient include 196 .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Ventilator-Associated</mesh_term>
	<mesh_term>Colistin</mesh_term>
	<criteria>Inclusion criterion Age old 18 yr Invasive mechanical ventilation 48 h Tracheostomized patient receive intermittent mechanical ventilation include VAP cause Gramnegative MDR bacteria resistant βlactams fluoroquinolones Exclusion criterion Extrapulmonary Gramnegative MDR infection require intravenous colimycin VAP associate bacteremia require combine treatment nebulized intravenous colimycin Hypersensitivity colistimethate , colistin base , polymyxins and/or excipients Porphyria Severe hypoxemia define PaO2 / FiO2 &lt; 100 ; venovenous ECMO initiate , patient include Severe brain injury ( initial Glasgow coma score &lt; 8 ) first 7 day randomization Myasthenia cystic fibrosis Refusal participate study Participation clinical study therapeutic investigational product within 30 day prior first day inclusion No affiliation social health insurance Patient guardianship Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Nebulized colistin</keyword>
	<keyword>Intravenous colistin</keyword>
	<keyword>ventilator-associated pneumonia</keyword>
	<keyword>multidrug resistance</keyword>
	<keyword>Gram-negative bacteria</keyword>
</DOC>